Effects of allisartan isoproxil combined with metformin on lipid metabolism,cardiac function and serum indicators in elderly hypertensive patients with diabetes
Objective To study the effect of allisartan isoproxil combined with metformin on elderly patients with hypertensive patients with diabetes.Methods Selected 82 cases of elderly patients with hypertensive patients with diabetes from August 2021 to May 2023,divided into the control group and the observation group randomly,41 cases in each group.The control group was treated with metformin,while the observation group was treated with allisartan isoproxil combined with metformin.The clinical efficacy,blood lipid indexes[total cholesterol(TC),low-density cholesterol(LDL-C)and triglycerides(TG)],cardiac function[stroke output(SV),left ventricular end-diastolic blood volume(EDV),cardiac output(CO),ejection fraction(EF)and left ventricular end-systolic blood volume(ESV)],serum indicators(miR-455,miR-126 and miR-26a-5p)of the two groups were measured.Results The total effective rate of the observation group was significantly higher(P＜0.05).After treatment,the levels of TC,LDL-C,and TG in both groups were significantly reduced(P＜0.05),and the levels of TC,LDL-C,and TG in the observation group were significantly lower(P＜0.05).After treatment,the SV,ESV,EF,CO and EDV of both groups were significantly improved(P＜0.05),and the SV,ESV,EF,CO and EDV of the observation group were significantly better(P＜0.05).After treatment,the serum levels of miR-455,miR-126,and miR-26a-5p in both groups were significantly increased(P＜0.05),and the serum levels of miR-455,miR-126,and miR-26a-5p in the observation group were significantly higher(P＜0.05).Conclusion Allisartan isoproxil combined with metformin has a significant effect on elderly patients with hypertension and diabetes.
Allisartan isoproxilMetforminHypertension with diabetesLipid metabolismCardiac functionSerum indicators
NETL
NSTL
万方数据
